{"filings":[{"id":760078,"accession_number":"0001006837-26-000045","cik":1006837,"company_name":"INNOVATE Corp.","ticker":"VATE","form_type":"8-K","filed_at":"2026-06-01T12:45:13+00:00","items":["1.01","2.03","7.01","9.01"],"status":"ready","headline":"INNOVATE to sell 75% of Broadcasting to CONX Corp.; $105M bridge loan refinances existing debt","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Net to INNOVATE: retains 25% of Broadcasting post-merger; CONX provides up to $75M equity commitment.","Bridge loan of $105M at 8.00% p.a. matures May 29, 2027; interest capitalized quarterly, extinguished upon merger close.","INNOVATE granted option to repurchase up to 15% of Broadcasting from CONX within 18 months post-close.","CONX Affiliate granted option to acquire up to 80.1% of Broadcasting within two years; INNOVATE may force buyout of its remaining stake.","Closing subject to FCC and HSR approvals; expected by November 29, 2026 with possible extensions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":164790000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":442760,"accession_number":"0001006837-26-000038","cik":1006837,"company_name":"INNOVATE Corp.","ticker":"VATE","form_type":"8-K","filed_at":"2026-05-14T20:11:26+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"INNOVATE Q1 revenue up 33% to $364.8M; net loss narrows to $17.2M; adjusted EBITDA rises 174% to $19.7M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Infrastructure segment revenue $357.9M (+35.1% YoY); DBMG reported backlog $1.6B, adjusted backlog $1.8B.","Life Sciences: MediBeacon received CE mark under EU MDR for Transdermal GFR Monitor and Reusable Sensor.","Spectrum revenue $5.3M (down 14.5% YoY) on advertising softness; collaborative trials underway with major carrier.","Net loss per diluted share improved to ($1.29) from ($1.89) YoY; Total Adjusted EBITDA $19.7M vs $7.2M.","Cash and cash equivalents $134.6M at March 31, 2026; non-operating corporate cash $2.5M."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.29,"consensus_revenue_estimate":null,"consensus_revenue_actual":364800000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":164790000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":90556,"accession_number":"0001006837-26-000021","cik":1006837,"company_name":"INNOVATE Corp.","ticker":"VATE","form_type":"8-K","filed_at":"2026-04-06T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"INNOVATE subsidiary DBM Global to pay $3M dividend; INNOVATE to receive ~$2.7M","summary_kind":"llm","event_type":"dividend","confidence":"high","bullets":["DBM Global to pay ~$3M cash dividend ($0.78/share) on April 28, 2026; record date April 13, 2026.","INNOVATE expects to receive ~$2.7M of the $3M total dividend as DBMG's largest stockholder.","INNOVATE's individual stockholders are not eligible for the DBMG dividend.","Dividend signals DBMG's cash position; proceeds flow to parent INNOVATE."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":164790000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":100175,"accession_number":"0001006837-26-000019","cik":1006837,"company_name":"INNOVATE Corp.","ticker":"VATE","form_type":"8-K","filed_at":"2026-03-31T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"INNOVATE's MediBeacon receives CE Mark for TGFR Monitor and Reusable Sensor under EU MDR","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["MediBeacon (equity method investment of INNOVATE) obtained EU CE Mark under MDR for TGFR Monitor and Reusable Sensor.","Devices are Class IIa; TGFR System enables transdermal assessment of kidney function (tGFR).","CE Mark allows potential use in European clinical trials; Lumitrace injection approved in U.S. and China.","Dr. Lui Forni plans to include transdermal GFR in his clinical research in Europe later this year."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":164790000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":100174,"accession_number":"0001006837-26-000013","cik":1006837,"company_name":"INNOVATE Corp.","ticker":"VATE","form_type":"8-K","filed_at":"2026-03-26T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"INNOVATE Q4 rev surges 62% to $382.7M; net loss narrows to $7.8M; backlog $1.8B","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 revenue $382.7M (+61.7% YoY); net loss $7.8M ($0.58 EPS) vs $16.9M loss a year ago.","FY 2025 revenue $1.246B (+12.5%); net loss $64.0M ($4.84 EPS) vs $35.8M loss in 2024.","Q4 total Adjusted EBITDA $24.5M (+63.3% YoY); FY Adj EBITDA $67.2M, down 5.8% from $71.3M.","DBMG (Infrastructure) backlog $1.8B, up from $1.1B a year ago; Q4 segment revenue $373.9M (+65.7%).","R2 Life Sciences secured 600-system minimum purchase commitment in China; MediBeacon got FDA approval for next-gen TGFR."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":164790000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":100173,"accession_number":"0001006837-26-000005","cik":1006837,"company_name":"INNOVATE Corp.","ticker":"VATE","form_type":"8-K","filed_at":"2026-02-10T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"MediBeacon TGFR article named 2025 JASN Editors’ Choice; commercial rollout started Jan 2026","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["MediBeacon's transdermal GFR article selected as one of five 2025 Editors' Choice articles by JASN.","TGFR System uses Lumitrace injection and transdermal sensor to measure kidney function at point of care.","INNOVATE holds 44.7% equity interest in MediBeacon; commercialization began Jan 2026 in select academic centers.","Initial clinical focus: heart failure monitoring, transplant evaluation, and oncology drug dosing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":164790000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":100172,"accession_number":"0001006837-26-000002","cik":1006837,"company_name":"INNOVATE Corp.","ticker":"VATE","form_type":"8-K","filed_at":"2026-02-02T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"INNOVATE's subsidiary DBM Global declares $5M cash dividend; VATE to receive ~$4.6M","summary_kind":"llm","event_type":"dividend","confidence":"high","bullets":["DBM Global declares $5M cash dividend ($1.30/share) payable Feb 24, 2026 to holders of record Feb 9, 2026.","INNOVATE, as largest DBMG stockholder, expects to receive approximately $4.6M of the total dividend.","INNOVATE's individual stockholders are not eligible to receive the cash dividend."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":164790000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":116510,"accession_number":"0001006837-25-000134","cik":1006837,"company_name":"INNOVATE Corp.","ticker":"VATE","form_type":"8-K","filed_at":"2025-12-16T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"INNOVATE's MediBeacon receives FDA approval for next-gen TGFR System","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["MediBeacon (44.7%-owned by VATE) gets FDA nod for TGFR System with reusable sensor.","Reusable sensor lowers cost vs prior single-use version; designed for patient comfort.","Initial sales at select US and China academic medical centers expected Q1 2026.","TGFR System featured as lead article in Journal of the American Society of Nephrology August 2025.","Transdermal GFR assessment does not require age, weight, sex, race, or ethnicity inputs."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":164790000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":116509,"accession_number":"0001006837-25-000126","cik":1006837,"company_name":"INNOVATE Corp.","ticker":"VATE","form_type":"8-K","filed_at":"2025-11-12T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"INNOVATE Q3 rev $347M (+43% YoY); net loss narrows to $9.4M; initiates sales processes for DBM Global and Spectrum","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $347.1M, up 43.3% YoY; net loss attributable to common/preferred $9.4M vs $15.3M; EPS -$0.71 vs -$1.18.","Total Adjusted EBITDA $19.8M (+17.9% YoY). Infrastructure revenue $338.4M (+45.4%); segment Adj. EBITDA $23.5M.","MediBeacon received NMPA approval to sell Transdermal GFR System in China; expects availability before year-end.","Missed Sep 1, 2025 debt milestone triggered mandatory sales process for DBM Global; missed Nov 1 milestone for HC2 Broadcasting.","Adjusted backlog for DBMG $1.6B; added $431M in new awards after Q3. Cash $35.5M at Sep 30 (vs $48.8M year-end 2024)."],"consensus_eps_estimate":null,"consensus_eps_actual":-4.27,"consensus_revenue_estimate":null,"consensus_revenue_actual":863300000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":164790000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":116508,"accession_number":"0001006837-25-000118","cik":1006837,"company_name":"INNOVATE Corp.","ticker":"VATE","form_type":"8-K","filed_at":"2025-10-21T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"MediBeacon receives NMPA approval for Transdermal GFR System in China; sales expected by year-end","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["NMPA approved Lumitrace (relmapirazin) injection and MediBeacon TGFR Monitor/Sensor for kidney function assessment in China.","TGFR system will be available for sale in China before end of 2025; commercial partnership with Huadong Medicine (est. 2019).","CKD affects ~11% of China's 1.4B people; TGFR offers point-of-care tGFR without blood draws or estimating equations."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":164790000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":116507,"accession_number":"0001006837-25-000115","cik":1006837,"company_name":"INNOVATE Corp.","ticker":"VATE","form_type":"8-K","filed_at":"2025-10-16T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"INNOVATE's DBM Global to pay $8.8M cash dividend; INNOVATE to receive ~$8M","summary_kind":"llm","event_type":"dividend","confidence":"high","bullets":["DBM Global will pay a cash dividend of $8.8 million ($2.28 per share) on Nov 10, 2025.","Record date for DBMG stockholders is Oct 27, 2025; INNOVATE is the largest stockholder.","INNOVATE expects to receive approximately $8 million of the total $8.8 million dividend.","The dividend is paid by DBM Global, not by INNOVATE, and INNOVATE's individual shareholders are not eligible."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":164790000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":132963,"accession_number":"0001006837-25-000112","cik":1006837,"company_name":"INNOVATE Corp.","ticker":"VATE","form_type":"8-K","filed_at":"2025-09-09T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"INNOVATE subsidiary R2 posts Q2 2025 revenue growth of 88% YoY; global system sales up 125%","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["R2's Q2 2025 revenue increased 88% vs Q2 2024; global system sales surged 125% YoY.","Outside North America, H1 2025 demand grew 768% vs same period in 2024.","Patient treatments rose 115% YoY in Q2 2025; average monthly utilization per provider up 28%.","Glacial Skin social media engagement outperforms industry benchmarks by 823%; website traffic up 141% QoQ."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":164790000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":132962,"accession_number":"0001006837-25-000103","cik":1006837,"company_name":"INNOVATE Corp.","ticker":"VATE","form_type":"8-K","filed_at":"2025-08-05T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"INNOVATE Q2 revenue falls 23% to $242M; net loss of $22M vs prior-year profit of $14.1M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $242M, down 22.7% YoY; net loss of $22M vs net income $14.1M in Q2 2024.","Diluted EPS -$1.67 vs +$1.03 (reverse split adjusted); Total Adj. EBITDA down 41.2% to $15.7M.","Infrastructure revenue $233.1M (-23.6%), backlog $1.3B; Life Sciences R2 unit sales up 124.5% YoY.","Completed refinancing on Aug 4 extending debt maturities; launched fourth ATSC 3.0 station."],"consensus_eps_estimate":null,"consensus_eps_actual":-3.56,"consensus_revenue_estimate":null,"consensus_revenue_actual":516200000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":164790000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":132961,"accession_number":"0001006837-25-000097","cik":1006837,"company_name":"INNOVATE Corp.","ticker":"VATE","form_type":"8-K","filed_at":"2025-08-05T23:59:59+00:00","items":["1.01","2.03","3.02","9.01"],"status":"ready","headline":"INNOVATE closes $360M 10.5% notes and $54M 9.5% convertible debt refinancing","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Issued $360.3M New Senior Secured Notes (10.5%, due Feb 2027); exchanged $328.1M of existing 8.5% 2026 notes; $1.9M old notes remain.","Issued $53.5M New Convertible Notes (9.5%, due Mar 2027) exchanging $48.7M of existing convertible notes; conversion price ~$42.31/share.","Extended revolving credit facility to Sep 2026; CGIC note amended to $43M at 16% PIK interest, secured, due Apr 2027 (includes preferred stock exchange).","Extended Spectrum Notes ($69.7M) to Sep 2026; must pursue strategic alternatives for Broadcasting segment if not repaid by Nov 2025.","Covenants require asset sales generating ≥$150M net proceeds with milestones through Feb 2026; failure triggers sale process for DBM Global."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":164790000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":132960,"accession_number":"0001006837-25-000085","cik":1006837,"company_name":"INNOVATE Corp.","ticker":"VATE","form_type":"8-K","filed_at":"2025-07-31T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"INNOVATE Corp. successfully exchanges 99.4% of 8.5% senior secured notes for 10.5% notes due 2027","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["US$328.1M of US$330M outstanding (99.41%) tendered for exchange; early settlement expected Aug 4, 2025.","New notes bear 10.5% interest, mature Feb 1, 2027; holders receive $1,072.50 principal per $1,000 exchanged.","Consents adopted to eliminate substantially all restrictive covenants and subordinate remaining existing notes.","Exchange offer conditioned on concurrent transactions including convertible note exchanges and credit extension amendments.","Early exchange premium extended to all valid tenders through expiration on Aug 13, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":164790000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":132959,"accession_number":"0001006837-25-000081","cik":1006837,"company_name":"INNOVATE Corp.","ticker":"VATE","form_type":"8-K","filed_at":"2025-07-28T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"INNOVATE's unit DBM Global to pay $4.4M cash dividend; INNOVATE expects $4M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["DBM Global declares $4.4M cash dividend ($1.14/share) payable Aug 21, 2025 to holders of record Aug 7, 2025.","INNOVATE, as largest DBM Global stockholder, expects to receive approximately $4M of the total dividend.","Dividend is not payable to INNOVATE's individual stockholders."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":164790000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":132958,"accession_number":"0001006837-25-000079","cik":1006837,"company_name":"INNOVATE Corp.","ticker":"VATE","form_type":"8-K","filed_at":"2025-07-17T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"INNOVATE launches $48.7M convertible exchange & $330M secured note exchange to extend debt maturities","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Exchange of $48.7M 7.5% Convertible Notes due 2026 for $51.1M 9.5% Convertible Notes due 2027, secured by second-priority lien.","Exchange offer for $330M 8.5% Senior Secured Notes due 2026 for new 10.5% Senior Secured Notes due Feb 2027; requires $150M asset sales.","Supporting noteholders (75.3% of existing secured notes) committed to tender; exchange offer condition requires 98% participation.","Agreements in principle to extend revolver to Sep 2026, CGIC note to Apr 2027 at 16% PIK, Spectrum notes to Sep 2026, R2 note to Aug 2026.","Early participation deadline July 30, 2025; early settlement expected Aug 4, final settlement Aug 15, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":164790000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":149513,"accession_number":"0001006837-25-000060","cik":1006837,"company_name":"INNOVATE Corp.","ticker":"VATE","form_type":"8-K","filed_at":"2025-06-12T23:59:59+00:00","items":["5.07","9.01"],"status":"ready","headline":"INNOVATE Corp. annual meeting elects directors, approves say-on-pay, ratifies BDO USA","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Four director nominees elected: Avram A. Glazer, Warren H. Gfeller, Brian S. Goldstein, Amy M. Wilkinson (avg ~8.85M for).","Non-binding say-on-pay approved with 8,651,492 for, 113,777 against.","Say-on-frequency vote chose one year with 8,784,603 for, 13,150 against.","BDO USA, P.C. ratified as independent auditor for FY2025 with 10,704,242 for."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":164790000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":149512,"accession_number":"0001006837-25-000054","cik":1006837,"company_name":"INNOVATE Corp.","ticker":"VATE","form_type":"8-K","filed_at":"2025-05-23T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"INNOVATE's subsidiary DBM Global declares $5.5M cash dividend; INNOVATE to receive ~$5M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["DBM Global will pay $5.5M ($1.42/share) cash dividend on June 16, 2025 to holders of record June 2, 2025.","INNOVATE expects to receive approximately $5M of the total dividend as DBMG's largest stockholder.","Individual INNOVATE stockholders are not eligible for the cash dividend."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":164790000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":149511,"accession_number":"0001006837-25-000050","cik":1006837,"company_name":"INNOVATE Corp.","ticker":"VATE","form_type":"8-K","filed_at":"2025-05-21T23:59:59+00:00","items":["1.01","1.02","2.03","7.01","9.01"],"status":"ready","headline":"DBM Global enters $220M credit facility to refinance debt, provide working capital","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["$85M term loan + $135M revolver (total $220M) from syndicate led by UMB Bank, N.A.","Facility matures May 20, 2030; accordion allows up to $50M additional capacity.","Proceeds used to fully repay existing debt and provide additional working capital.","CEO Rustin Roach and interim CEO Paul Voigt highlight liquidity to support growth."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":164790000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":149510,"accession_number":"0001006837-25-000044","cik":1006837,"company_name":"INNOVATE Corp.","ticker":"VATE","form_type":"8-K","filed_at":"2025-05-06T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"INNOVATE Q1 revenue $274.2M (-13% YoY); net loss widens to $24.8M; MediBeacon TGFR gets FDA approval","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $274.2M, down 13% YoY; net loss attributable to common $24.8M ($1.89 per share), vs $17.7M loss YoY.","DBM Global revenue $264.9M (-14% YoY); adjusted backlog $1.4B, added over $500M in new awards.","MediBeacon TGFR system received FDA approval in Jan to assess kidney function; also NMPA China approval.","Life Sciences R2 revenue tripled to $3.1M; unit sales up 163% YoY.","Spectrum revenue $6.2M; signed contract for two new OTA networks; datacasting revenue expected by year-end."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.89,"consensus_revenue_estimate":null,"consensus_revenue_actual":274200000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":164790000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":168584,"accession_number":"0001006837-25-000020","cik":1006837,"company_name":"INNOVATE Corp.","ticker":"VATE","form_type":"8-K","filed_at":"2025-03-31T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"INNOVATE reports Q4 revenue down 34.5% to $236.6M; net loss widens to $16.9M; MediBeacon TGFR receives FDA approval","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2024 revenue $236.6M (-34.5% YoY); net loss attributable to common $16.9M ($1.29 loss per share).","Full year 2024 revenue $1.11B (-22.2% YoY); Adjusted EBITDA $71.3M (+9.7% YoY).","Infrastructure segment Q4 revenue $225.7M (-36.2%); adjusted backlog $1.1B; added >$500M to backlog post-year-end.","MediBeacon TGFR received FDA approval Jan 2025 for kidney function assessment; also NMPA approval in China Feb 2025.","Broadcasting Q4 revenue $6.8M (+19.3% YoY); Life Sciences revenue $4.1M (R2 unit sales +113% Q4 YoY)."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.89,"consensus_revenue_estimate":null,"consensus_revenue_actual":274200000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":164790000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":168583,"accession_number":"0001006837-25-000007","cik":1006837,"company_name":"INNOVATE Corp.","ticker":"VATE","form_type":"8-K","filed_at":"2025-03-06T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"INNOVATE extends revolving credit facility maturity to Aug 1, 2025","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Sixth Amendment to Credit Agreement dated March 13, 2020, with MSD PCOF Partners IX, LLC as lender.","Borrower: INNOVATE Corp.; guarantors: INNOVATE 2 Corp. and DBM Global Intermediate Holdco Inc.","Maturity of senior secured revolving credit facility extended to August 1, 2025.","No changes to principal amount, interest rate, or other material terms disclosed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":164790000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":168582,"accession_number":"0001006837-25-000005","cik":1006837,"company_name":"INNOVATE Corp.","ticker":"VATE","form_type":"8-K","filed_at":"2025-02-25T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"MediBeacon's Transdermal GFR Monitor and Sensor approved by China NMPA; Lumitrace under review","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["China NMPA approved MediBeacon TGFR Monitor and Sensor for kidney function assessment; Lumitrace injection still under review, target approval late 2025.","FDA approved the TGFR system on Jan 17, 2025; MediBeacon developing next-gen TGFR with updated software.","Published studies: eGFR misclassified 35% of CKD patients; transdermal GFR showed r²=0.90 correlation with plasma mGFR across skin types.","MediBeacon CEO highlighted partnership with Huadong Medicine for China rollout of the TGFR system."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":164790000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":168581,"accession_number":"0001006837-25-000002","cik":1006837,"company_name":"INNOVATE Corp.","ticker":"VATE","form_type":"8-K","filed_at":"2025-01-21T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"MediBeacon TGFR System Receives FDA Approval for Kidney Function Assessment","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA approved MediBeacon Transdermal GFR (tGFR) for assessing kidney function in adults with normal or impaired renal function without input of age, sex, race.","TGFR uses a non-radioactive fluorescent agent (Lumitrace) with a transdermal sensor; no blood draws or urine analysis needed.","Primary efficacy endpoint met: P30 value of 94% (95% CI: 89.4%-96.9%) in clinical study across GFR ranges and skin tones.","More than 800 million people globally have chronic kidney disease; TGFR aims to improve point-of-care assessment."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":164790000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":185698,"accession_number":"0001006837-24-000161","cik":1006837,"company_name":"INNOVATE Corp.","ticker":"VATE","form_type":"8-K","filed_at":"2024-11-20T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"INNOVATE portfolio co R2 Technologies reports record Q2/Q3: unit sales up 294% YoY","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["R2 Q2/Q3: 294% increase in worldwide Glacial Skin system unit sales vs prior year.","Patients treated up 168%; avg monthly utilization per provider up 58% YoY.","Q3 social media mentions surged 4,086%; record-high impressions across platforms.","New partnerships with Woodhouse Spas (100 locations) and skincare brands Epicutis, iS CLINICAL, BABOR, BioSkin.","Launched Glacialist Ambassador Program and colder Glacial Glide Rx protocol."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":164790000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":185697,"accession_number":"0001006837-24-000154","cik":1006837,"company_name":"INNOVATE Corp.","ticker":"VATE","form_type":"8-K","filed_at":"2024-11-06T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"INNOVATE Q3 revenue $242.2M (-35.5% YoY); net loss $15.3M vs $7.3M loss YoY","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["DBM Global revenue $232.8M (-37% YoY); gross margins expanded 360 bps to 18.8%","R2 record worldwide system unit sales growth of 416% YoY; $3.0M Life Sciences revenue","Spectrum revenue $6.4M (+$1M YoY); Adjusted EBITDA turned positive to $1.7M","Consolidated Adjusted EBITDA $16.8M (-24% YoY); cash $51.0M vs $80.8M Dec 2023","Reverse stock split 1-for-10 effected Aug 8, 2024; EPS retroactively adjusted"],"consensus_eps_estimate":null,"consensus_eps_actual":-1.69,"consensus_revenue_estimate":null,"consensus_revenue_actual":870500000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":164790000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":202262,"accession_number":"0001006837-24-000129","cik":1006837,"company_name":"INNOVATE Corp.","ticker":"VATE","form_type":"8-K","filed_at":"2024-09-03T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"INNOVATE Corp. regains NYSE minimum share price compliance","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received NYSE notice on August 27, 2024 that it regained compliance with Section 802.01C.","Must maintain average closing share price of at least $1.00 over 30 trading days.","CEO Paul Voigt says regaining compliance allows focus back on growth story.","Company common stock (VATE) continues trading on NYSE without listing concern."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":164790000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":202261,"accession_number":"0001006837-24-000124","cik":1006837,"company_name":"INNOVATE Corp.","ticker":"VATE","form_type":"8-K","filed_at":"2024-08-08T23:59:59+00:00","items":["5.03","8.01","9.01"],"status":"ready","headline":"INNOVATE Corp. executes 1-for-10 reverse stock split effective Aug 8, 2024","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Board-approved 1-for-10 reverse split filed in Delaware Aug 8, 2024; effective 5:00 p.m. ET same day.","Every 10 existing common shares auto-converted into 1 new share; symbol VATE unchanged.","Exercise prices, shares under equity awards, convertible notes, and preferred stock proportionally adjusted.","Authorized shares and par value ($0.001) unchanged; split-adjusted trading begins Aug 9, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":164790000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":202260,"accession_number":"0001006837-24-000121","cik":1006837,"company_name":"INNOVATE Corp.","ticker":"VATE","form_type":"8-K","filed_at":"2024-08-07T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"INNOVATE Q2 net income $14.1M vs loss $10.5M YoY; revenue $313M (-15%), adj. EBITDA $26.7M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $313.1M (-15.1% YoY); net income $14.1M vs loss $10.5M; diluted EPS $0.10 vs ($0.13).","Infrastructure: DBM Global revenue $305.2M (-15.8%) but net income $21.0M (vs $7.0M); adj. EBITDA $32.5M; gross margin expanded 650 bps to 20.2%.","Life Sciences: R2 Glacial system record North America sales, 200% increase YoY; MediBeacon continues FDA kidney monitoring review.","Spectrum: Broadcasting revenue $6.2M (+8.8%), adj. EBITDA $1.5M (vs $0.8M); launched third network Defy.","Board approved 1-for-10 reverse stock split, effective August 9, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.03,"consensus_revenue_estimate":null,"consensus_revenue_actual":628300000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":164790000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":218354,"accession_number":"0001006837-24-000103","cik":1006837,"company_name":"INNOVATE Corp.","ticker":"VATE","form_type":"8-K","filed_at":"2024-06-20T23:59:59+00:00","items":["3.02","5.03","5.07","9.01"],"status":"ready","headline":"INNOVATE shareholders approve reverse split, authorized shares increase; 44.7M shares converted","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Shareholders approved reverse stock split of common stock (69.5M for, 3.6M against).","Authorized common shares increased from 160M to 250M (63.1M for, 9.6M against).","Lancer Capital issued 31,286 Series C Preferred shares, converting into 44,693,895 common shares.","Conversion of Series C Preferred into common stock was also shareholder-approved (58.98M for).","Additional approvals: officer exculpation charter amendment and equity plan share increase."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":164790000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":218353,"accession_number":"0001006837-24-000092","cik":1006837,"company_name":"INNOVATE Corp.","ticker":"VATE","form_type":"8-K","filed_at":"2024-06-14T23:59:59+00:00","items":["5.07","8.01","9.01"],"status":"ready","headline":"Innovate Corp. annual meeting adjourned due to technical issues; reconvened June 18","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Annual meeting scheduled June 13 adjourned without business due to third-party hosting site technical difficulties.","Meeting will reconvene June 18 at 12:00 noon ET via same webcast link.","Stockholders can attend, vote, and submit questions at reconvened meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":164790000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":218352,"accession_number":"0001006837-24-000078","cik":1006837,"company_name":"INNOVATE Corp.","ticker":"VATE","form_type":"8-K","filed_at":"2024-05-07T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"INNOVATE Q1 revenue $315M (-0.8%); net loss $17.7M, adj EBITDA $12.8M (+161%)","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $315.2M (down 0.8% YoY); net loss attributable to common $17.7M vs $10.2M loss in Q1 2023.","Total adjusted EBITDA $12.8M (up 161% YoY), driven by margin expansion at DBMG and cost cuts at R2.","Infrastructure revenue $307.9M, net income $4.4M; backlog $0.9B reported, $1.2B adjusted.","Life Sciences: R2 record North America system sales (400+ units); MediBeacon in ongoing FDA discussions.","Closed rights offering Apr 24: issued 5.3M common at $0.70 ($3.7M) and 31.3K preferred to Lancer ($31.3M)."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.22,"consensus_revenue_estimate":null,"consensus_revenue_actual":315200000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":164790000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":218351,"accession_number":"0001006837-24-000053","cik":1006837,"company_name":"INNOVATE Corp.","ticker":"VATE","form_type":"8-K","filed_at":"2024-04-24T23:59:59+00:00","items":["3.02","8.01","9.01"],"status":"ready","headline":"INNOVATE Corp. closes rights offering, raising $35M from common shares and Lancer Capital preferred stock.","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Rights offering expired Apr. 19, 2024; 5.3M common shares at $0.70/share raised $3.7M in gross proceeds.","Lancer Capital (Avram Glazer) purchased 31.3K shares of Series C preferred stock at $1,000/share for $31.3M total.","After offering, INNOVATE has 85.2M common shares outstanding; conversion of preferred could add 44.7M shares.","Proceeds from rights offering to be used for general corporate purposes, debt service, and working capital."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":164790000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":218350,"accession_number":"0001006837-24-000050","cik":1006837,"company_name":"INNOVATE Corp.","ticker":"VATE","form_type":"8-K","filed_at":"2024-04-22T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"INNOVATE Corp. announces preliminary results of rights offering; expects ~$35M gross proceeds","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["18.1M basic subscription rights exercised to purchase 5.2M shares of common stock at $0.70/share.","0.1M additional shares subscribed under over-subscription privilege, subject to proration.","Lancer Capital (led by Chairman Avram Glazer) to purchase 15.3K preferred shares at $1,000/share under backstop.","Total gross proceeds of ~$35M from rights offering and concurrent private placement.","Proceeds to be used for general corporate purposes including debt service and working capital."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":164790000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":218349,"accession_number":"0001006837-24-000044","cik":1006837,"company_name":"INNOVATE Corp.","ticker":"VATE","form_type":"8-K","filed_at":"2024-04-09T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"INNOVATE Corp. extends $19M rights offering deadline to April 19","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Rights offering for common stock, originally $19M, extended to 5:00 p.m. ET on April 19, 2024.","Initial expiration was March 25; previously extended to April 9; further extension announced April 9.","Eligible participants: holders of common stock, Series A-3 and A-4 preferred stock, and 2026 Convertible Notes as of March 6.","Extension allows additional time for stockholders and noteholders to participate in the offering."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":164790000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":238287,"accession_number":"0001006837-24-000038","cik":1006837,"company_name":"INNOVATE Corp.","ticker":"VATE","form_type":"8-K","filed_at":"2024-03-28T23:59:59+00:00","items":["3.02","5.03","9.01"],"status":"ready","headline":"INNOVATE Corp. raises $25M via Series C convertible preferred sale to Lancer Capital","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Issued 25,000 shares of Series C Non-Voting Convertible Preferred to Lancer Capital for $25M.","Buyer Lancer Capital is led by Chairman Avram A. Glazer; placement exempt under Section 4(a)(2).","Initial conversion price $0.70 per share; shares automatically convert upon stockholder approval.","Dividends equal to common dividends; redemption price $1,000 plus 8% annual after 6 years.","Company to seek stockholder approval for conversion at 2024 annual meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":164790000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":238286,"accession_number":"0001006837-24-000034","cik":1006837,"company_name":"INNOVATE Corp.","ticker":"VATE","form_type":"8-K","filed_at":"2024-03-25T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"INNOVATE extends $19M rights offering subscription period to April 9, 2024","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Extends $19M common stock rights offering subscription period to 5:00 p.m. ET on April 9, 2024.","Eligible participants include holders of common stock, Series A-3/A-4 preferred, and 2026 Convertible Notes as of March 6.","Rights offering conducted under previously filed shelf registration statement (effective Oct 6, 2023)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":164790000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":238285,"accession_number":"0001006837-24-000031","cik":1006837,"company_name":"INNOVATE Corp.","ticker":"VATE","form_type":"8-K","filed_at":"2024-03-20T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"INNOVATE Corp. amends 10-K auditor consent to fix omitted S-3 reference","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Revised consent of BDO USA, P.C. now includes reference to Form S-3 (No. 333-274760).","No changes to previously reported financial results or any other 10-K disclosures.","Original 10-K filed March 6, 2024; amendment filed March 20, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.05,"calibrated_materiality_score":0.05,"market_cap_usd":164790000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}